Cord Clamping Among Neonates With Congenital Heart Disease
Recruiting
The goal of this clinical trial is to compare 2 different timepoints for clamping the umbilical cord at birth for term-born infants with a prenatal diagnosis of congenital heart disease (CHD). The main questions it aims to answer are: * Does Delayed Cord Clamping at 120 seconds (DCC-120) or Delayed Cord Clamping at 30 seconds (DCC-30) after birth lead to better health outcomes? * Does DCC-120 seconds or DCC-30 seconds after birth lead to better neuromotor outcomes at 22-26 months of infant age... Read More
Gender:
ALL
Ages:
Between 37 weeks and 42 weeks
Trial Updated:
07/31/2025
Locations: Children's of Alabama, Birmingham, Alabama +20 locations
Conditions: Congenital Heart Disease (CHD)
Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma
Recruiting
The purpose of this study is to better understand how safe and effective the drug cabozantinib in combination with high-dose ifosfamide is in the treatment of children and adults with relapsed/refractory Ewing sarcoma and osteosarcoma.
Gender:
ALL
Ages:
Between 5 years and 40 years
Trial Updated:
07/31/2025
Locations: University of California San Francisco, San Francisco, California +3 locations
Conditions: Ewing Sarcoma, Osteosarcoma
Early Age-Related Hearing Loss Investigation (EARHLI)
Recruiting
Early Age-Related Hearing Loss Investigation (EARHLI) is a single site study that will randomize late middle age adults to either a hearing intervention (including hearing aids) or a health education intervention. Participants will be followed for 1 year. This study will provide information on reducing cognitive decline in those at risk for Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD).
Gender:
ALL
Ages:
Between 55 years and 75 years
Trial Updated:
07/31/2025
Locations: Columbia University Medical Center, New York, New York
Conditions: Alzheimer Disease, Hearing Loss, Cognitive Impairment
Integrating Nonpharmacologic Strategies for Pain With Inclusion, Respect, and Equity
Recruiting
INSPIRE creates a trilingual mobile app and telehealth coaching program to promote non-pharmacologic strategies for pain management with Black, Chinese, and Latinx communities in the San Francisco Bay Area. Years 1-2 will develop the app and test it with a brief single arm pilot starting in Nov 2023. A full two arm randomized controlled trial (RCT) will being in early 2025 with changes in PEG scores as the primary outcome. Secondary outcomes include Helping to End Addiction Longterm (HEAL) commo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: San Francisco General Hospital, San Francisco, California +1 locations
Conditions: Chronic Pain
Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Bleeding
Recruiting
A prospective, multi-center, noninferiority randomized controlled trial designed to compare the efficacy of UI-EWD (Nexpowder™) hemostatic powder versus conventional endoscopic hemostatic therapy in patients presenting with acute overt gastrointestinal bleeding which is found at endoscopy to be due to one of the following sources: a gastric or duodenal ulcer with active bleeding (spurting or oozing) or a non-bleeding visible vessel; an esophageal, gastric or duodenal tumor with active bleeding o... Read More
Gender:
ALL
Ages:
22 years and above
Trial Updated:
07/31/2025
Locations: University of Alabama, Birmingham, Alabama +14 locations
Conditions: Acute Gastrointestinal Bleeding
Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)
Recruiting
Background: Neurofibromatosis type 1 (NF1) is a genetic disease that can cause many symptoms. About half of people with NF1 will develop benign (noncancerous) tumors along nerves in the skin, brain, and other parts of the body. Sometimes, though, these tumors can become cancerous. Researchers do not yet know how to predict which tumors will become cancerous. Objective: To test a new method for predicting which benign NF1 tumors will become cancerous. Eligibility: People aged 3 years and old... Read More
Gender:
ALL
Ages:
Between 3 years and 120 years
Trial Updated:
07/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Neurofibromatosis 1, Nerve Sheath Neoplasms
Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism
Recruiting
Background: The adrenal glands are 2 small organs that sit on top of each kidney. They release hormones; these are chemicals that control how the body works. Tumors on or outside the adrenal glands are called functional if they release hormones; they are called nonfunctional if they do not. Doctors who treat adrenal tumors need to know which type a person has. Researchers want to find better ways to learn whether an adrenal tumor is functional. Objective: To see if a new radioactive tracer (\... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Hyperaldosteronism, Hypercortisolism, Cushing s Syndrome
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
Recruiting
Background: Endometrial cancer (EC) of the uterus is becoming more common in the US. Sometimes EC often has increased levels of a protein called HER2. Cancers with HER2 tend to be more aggressive and have poorer outcomes. Objective: To test 2 study drugs-a vaccine that targets HER2 (AdHER2DC) plus a drug that supercharges immune cells that kill tumor cells (N-803)-combined with 2 FDA-approved cancer treatment drugs in people with EC. Eligibility: Adults aged 18 and older with HER2-positive... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Endometrial Cancer, Cancer of Endometrium, Carcinoma of Endometrium, Endometrial Carcinoma
Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation
Recruiting
The participants of this study will be of any age who are exposed to at least 1 dose of odevixibat at any time during pregnancy (from 1 day prior to conception to pregnancy outcome) and/or at any time during lactation (up to 12 months of infant age or weaning, whichever comes first. This study will collect data obtained via a variety of sources, including enrolled pregnant or lactating participants, the healthcare providers (HCP) involved in their care or the care of their infants, if applicabl... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
07/31/2025
Locations: Virtual Research Coordination Center Odevixibat (BYLVAY) Pregnancy Surveillance Program, Wilmington, North Carolina
Conditions: Pregnancy Related
Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33)
Recruiting
The proposed project aims to test the cognitive and neural effects of a cognitive training in a sample of individuals seeking treatment for anxiety, depression, or traumatic stress symptoms. Participants will be randomly assigned to one of two groups. Group 1 will receive a computer-based program that is designed as a cognitive training intervention and Group 2 will receive a similar computer-based exercise that researchers think will be less effective in training thinking skills (also known as... Read More
Gender:
ALL
Ages:
Between 21 years and 55 years
Trial Updated:
07/31/2025
Locations: UC San Diego, San Diego, California
Conditions: Anxiety Disorders, Depression, Post Traumatic Stress Disorder
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Recruiting
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places, including cancers in organs or tissues that have spread from their original site to nearby tissues or other parts of the body. In this study, all participants will receive the study drug, which will... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: The Angeles Clinic and Research Institute - California, Los Angeles, California +11 locations
Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Solid Tumor
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
Recruiting
This is a Phase III, international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function who had a recent HF event. The aim is to evaluate the effect of balcinrenone/dapagliflozin vs dapagliflozin, given once daily on top of other classes of SoC, on CV death and HF events.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/31/2025
Locations: Research Site, Alexander City, Alabama +792 locations
Conditions: Heart Failure and Impaired Kidney Function